1. Home
  2. LICN vs SPRO Comparison

LICN vs SPRO Comparison

Compare LICN & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lichen China Limited

LICN

Lichen China Limited

HOLD

Current Price

$1.30

Market Cap

116.4M

Sector

N/A

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.75

Market Cap

135.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LICN
SPRO
Founded
2004
2013
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
116.4M
135.5M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
LICN
SPRO
Price
$1.30
$2.75
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
488.4K
663.0K
Earning Date
04-28-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
111.81
EPS
N/A
N/A
Revenue
N/A
$66,802,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$300.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
39.24
52 Week Low
$0.75
$1.80
52 Week High
$9.49
$3.09

Technical Indicators

Market Signals
Indicator
LICN
SPRO
Relative Strength Index (RSI) 34.05 55.10
Support Level $0.75 $2.18
Resistance Level $3.33 $2.90
Average True Range (ATR) 1.28 0.17
MACD -0.51 0.03
Stochastic Oscillator 6.63 57.04

Price Performance

Historical Comparison
LICN
SPRO

About LICN Lichen China Limited

Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational, and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and the sales of financial and taxation training software.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: